Preliminary clinical trial data of HCC adoptive T cell therapy showed considerable antitumor activity of CAR-T cells targeting CD133 and GPC3,31,32 highlighting the prominent therapeutic value of adoptive T cell therapy in HCC patients. The gene discussed is PROM1; the disease is hepatocellular carcinoma.